Interestingly and predictably various BPs are restarting the Amyloid clearing drugs in clinical trials based on the FDA awarding Biogen approval of Aduhelm based on clearing Amyloid. Apparently one can not educate the ignorant FDA on science matters and there is no cure for unmitigated greed. <br /> Let us see what the UK and the EU where there maybe some semblance of patient outcomes and cost effectiveness in regulatory decisions will do with this Aduhelm fiasco. There is no difference between Socialized medicine and the American model on the bottom line of those that ultimately bear the cost. Only in the tyranny of how those costs are applied and how some Corporations like Biogen can unjustly enrich themselves.